ACR Appropriateness Criteria® on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II

Faguet, 1995, Hodgkin's disease: basing treatment decisions on prognostic factors, Leuk Lymphoma, 17, 223, 10.3109/10428199509056826 Gobbi, 2004, The clinical value of tumor burden at diagnosis in Hodgkin lymphoma, Cancer, 101, 1824, 10.1002/cncr.20568 Mendenhall, 1994, The role of prognostic factors in treatment selection for early-stage Hodgkin's disease, Am J Clin Oncol, 17, 189, 10.1097/00000421-199406000-00002 Specht, 1996, Prognostic factors in Hodgkin's disease, Semin Radiat Oncol, 6, 146, 10.1016/S1053-4296(96)80012-9 Carbone, 1971, Report of the Committee on Hodgkin's Disease Staging Classification, Cancer Res, 31, 1860 Crnkovich, 1987, Stage I to IIB Hodgkin's disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy, J Clin Oncol, 5, 1041, 10.1200/JCO.1987.5.7.1041 Hopper, 1991, Mediastinal bulk in Hodgkin disease, Invest Radiol, 26, 1101, 10.1097/00004424-199112000-00015 Bonfante, 1992, Early stage Hodgkin's disease: ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP, Eur J Cancer, 29A, 24 Hagemeister, 1994, Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy, Semin Hematol, 31, 36 Noordijk, 2006, Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials, J Clin Oncol, 24, 3128, 10.1200/JCO.2005.05.2746 Borchmann P, Diehl V, Goergen H, et al. Combined modality treatment with intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavourable Hodgkin Lymphoma (HL): final analysis of the German Hodgkin Study Group (GHSG) HD11 trial. Presented at: ASH Annual Meeting; New Orleans, La; 2009. Horning, 2002, Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial, J Clin Oncol, 20, 630, 10.1200/JCO.20.3.630 Ferme C, Divine M, Vranovsky A, et al. Four ABVD and involved-field radiotherapy in unfavorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): preliminary results of the EORTC-GELA H9-U trial.Presented at: ASH Annual Meeting; 2005. Borchmann P, Engert A, Pluetschow A, et al. Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Presented at: ASH Annual Meeting;2008. Ferme, 2007, Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease, N Engl J Med, 357, 1916, 10.1056/NEJMoa064601 Pavlovsky, 1988, Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease, J Natl Cancer Inst, 80, 1466, 10.1093/jnci/80.18.1466 Laskar, 2004, Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?, J Clin Oncol, 22, 62, 10.1200/JCO.2004.01.021 Meyer, 2005, Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group, J Clin Oncol, 23, 4634, 10.1200/JCO.2005.09.085 Engert, 2003, J Clin Oncol, 21, 3601, 10.1200/JCO.2003.03.023 Bonadonna, 2004, ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results, J Clin Oncol, 22, 2835, 10.1200/JCO.2004.12.170 Yahalom, 2002, The involved field is back: issues in delineating the radiation field in Hodgkin's disease, Ann Oncol, 13, 79, 10.1093/annonc/13.S1.79 Girinsky, 2006, Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines, Radiother Oncol, 79, 270, 10.1016/j.radonc.2006.05.015 Gallamini, 2007, Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study, J Clin Oncol, 25, 3746, 10.1200/JCO.2007.11.6525 Picardi, 2007, Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans, Leukemia Lymphoma, 48, 1721, 10.1080/10428190701559140